Hologic Company Insiders

HOLX Stock  USD 75.10  0.18  0.24%   
Hologic's insiders are aggressively selling. The analysis of insiders' sentiment of trading Hologic stock suggests that vertually all insiders are panicking at this time. Hologic employs about 7 K people. The company is managed by 41 executives with a total tenure of roughly 255 years, averaging almost 6.0 years of service per executive, having 170.49 employees per reported executive.
Jay Stein  Chairman
Co-Founder, Chairman Emeritus, Chief Technical Officer and Sr. VP
Stephen MacMillan  Chairman
Chairman, CEO and Pres

Hologic's Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-03-14Scott T GarrettDisposed 16441 @ 75.5View
2024-03-08Charles J DockendorffDisposed 1465 @ 76.21View
2024-01-29Karleen Marie ObertonDisposed 14940 @ 75View
2023-12-11Scott T GarrettDisposed 10000 @ 68.71View
2023-11-21Essex D MitchellDisposed 7500 @ 71.85View
2023-06-15Scott T GarrettDisposed 10000 @ 79.72View
2023-05-05Essex D MitchellDisposed 2390 @ 83.73View
Monitoring Hologic's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hologic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Hologic Stock please use our How to Invest in Hologic guide.

Hologic's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Hologic's future performance. Based on our forecasts, it is anticipated that Hologic will maintain a workforce of slightly above 6990 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Hologic's latest congressional trading

Congressional trading in companies like Hologic, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Hologic by those in governmental positions are based on the same information available to the general public.
2023-01-11Senator Thomas R. CarperAcquired Under $15KVerify
2022-11-30Representative Susie LeeDisposed Under $15KVerify
2021-03-12Representative Tom MalinowskiDisposed Under $15KVerify
2020-11-05Representative Katherine M. ClarkDisposed Under $15KVerify
2019-02-28Senator Jack ReedAcquired Under $15KVerify
2018-05-04Senator Susan M. CollinsAcquired $15K to $50KVerify
2016-12-01Senator Susan M CollinsAcquired $15K to $50KVerify

Hologic Management Team Effectiveness

The company has return on total asset (ROA) of 0.0649 % which means that it generated a profit of $0.0649 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1057 %, meaning that it created $0.1057 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Hologic's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.09 in 2024, whereas Return On Capital Employed is likely to drop 0.08 in 2024. At this time, Hologic's Asset Turnover is fairly stable compared to the past year.
Net Income Applicable To Common Shares is likely to rise to about 550.6 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 167.9 M in 2024.

Hologic Workforce Comparison

Hologic is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 214,848. Hologic holds roughly 6,990 in number of employees claiming about 3% of equities under Health Care industry.

Hologic Profit Margins

The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.22 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.22.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.390.46
Fairly Down
Very volatile
Net Profit Margin0.110.1
Significantly Up
Pretty Stable
Operating Profit Margin0.160.15
Notably Up
Pretty Stable
Pretax Profit Margin0.160.15
Notably Up
Slightly volatile
Return On Assets0.03370.0574
Way Down
Pretty Stable
Return On Equity0.08590.0818
Sufficiently Up
Very volatile

Hologic Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hologic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hologic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Hologic insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
1.4286
20
14
 81,895 
 104,615 
2023-12-01
0.675
27
40
 408,829 
 270,502 
2023-09-01
1.0
2
2
 2,886 
 1,064,954 
2023-03-01
3.8
19
5
 55,563 
 19,973 
2022-12-01
0.6087
28
46
 606,506 
 497,617 
2022-06-01
0.3333
3
9
 10,896 
 33,680 
2022-03-01
16.0
16
1
 66,048 
 2,179 
2021-12-01
0.9565
22
23
 709,494 
 142,271 
2021-09-01
0.4
2
5
 31,683 
 63,717 
2021-03-01
5.0
15
3
 54,127 
 22,892 
2020-12-01
0.6977
30
43
 1,394,986 
 694,422 
2020-09-01
0.25
3
12
 23,447 
 95,855 
2020-06-01
0.5833
7
12
 279,980 
 537,160 
2020-03-01
1.5
21
14
 338,419 
 513,160 
2019-12-01
0.8065
25
31
 682,229 
 500,257 
2019-09-01
0.1667
2
12
 223,762 
 485,005 
2019-03-01
2.5714
18
7
 82,125 
 44,136 
2018-12-01
0.8537
35
41
 656,768 
 246,967 
2018-09-01
0.1429
2
14
 16,694 
 108,953 
2018-06-01
0.6
6
10
 31,245 
 48,230 
2018-03-01
2.2222
20
9
 93,218 
 28,142 
2017-12-01
1.0851
51
47
 1,997,456 
 682,613 
2017-09-01
0.3077
4
13
 18,200 
 76,626 
2017-06-01
0.6119
41
67
 338,886 
 502,654 
2017-03-01
1.0526
40
38
 406,575 
 425,226 
2016-12-01
0.9375
45
48
 1,081,473 
 605,813 
2016-09-01
0.6
6
10
 38,521 
 68,992 
2016-06-01
0.5263
10
19
 76,009 
 119,993 
2016-03-01
2.0588
35
17
 162,758 
 60,169 
2015-12-01
0.9474
36
38
 522,261 
 192,212 
2015-09-01
0.5862
17
29
 372,964 
 6,705,928 
2015-06-01
0.3864
17
44
 112,618 
 273,029 
2015-03-01
1.7917
43
24
 363,246 
 272,609 
2014-12-01
1.0789
41
38
 921,812 
 148,788 
2014-09-01
0.6
3
5
 52,392 
 60,038 
2014-06-01
0.75
21
28
 599,638 
 635,118 
2014-03-01
3.5
28
8
 790,442 
 329,493 
2013-12-01
0.8451
60
71
 38,847,284 
 67,825,212 
2013-09-01
0.2143
9
42
 532,487 
 2,076,099 
2013-06-01
0.5
4
8
 80,807 
 135,558 
2013-03-01
1.1481
31
27
 406,147 
 964,629 
2012-12-01
0.5102
25
49
 1,101,677 
 320,004 
2012-09-01
0.5217
12
23
 506,846 
 736,633 
2012-06-01
0.5714
4
7
 75,000 
 103,985 
2012-03-01
1.2222
22
18
 237,525 
 238,014 
2011-12-01
0.7059
24
34
 1,152,764 
 360,740 
2011-06-01
0.5
3
6
 159,308 
 425,308 
2011-03-01
0.2895
11
38
 97,805 
 372,784 
2010-12-01
0.6667
14
21
 367,215 
 54,580 
2010-03-01
0.5
8
16
 73,282 
 440,658 
2009-12-01
0.7143
15
21
 674,328 
 165,413 
2009-09-01
0.5
3
6
 315,000 
 630,000 
2009-06-01
1.6
8
5
 103,138 
 146,000 
2009-03-01
0.6667
4
6
 49,150 
 174,000 
2008-12-01
12.0
12
1
 1,193,000 
 27,005 
2008-06-01
3.5
7
2
 20,000 
 19,901 
2008-03-01
3.0
18
6
 726,005 
 94,000 
2007-12-01
1.0968
136
124
 6,743,287 
 4,154,401 
2007-03-01
0.6842
13
19
 637,500 
 1,253,000 
2006-12-01
1.0
6
6
 21,694 
 42,000 
2006-03-01
1.0
3
3
 26,000 
 45,000 
2005-12-01
0.7273
8
11
 83,500 
 157,000 
2005-09-01
1.0
4
4
 49,000 
 48,000 
2005-06-01
0.6667
2
3
 6,250 
 12,500 
2005-03-01
0.625
20
32
 339,750 
 759,570 
2004-12-01
1.3333
8
6
 90,500 
 23,500 
2004-09-01
1.2
6
5
 93,906 
 20,562 
2004-03-01
1.0
12
12
 48,565 
 42,627 

Hologic Notable Stakeholders

A Hologic stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Hologic often face trade-offs trying to please all of them. Hologic's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Hologic's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jay SteinCo-Founder, Chairman Emeritus, Chief Technical Officer and Sr. VPProfile
Stephen MacMillanChairman, CEO and PresProfile
Sanjay PrabhakaranRegional President - AsiaProfile
Claus EgstrandSenior Vice President General Manager - InternationalProfile
Jennifer SchneidersPresident SolutionsProfile
Jan VerstrekenRegional President - Europe,Middle EastandAfrica(EMEA) and CanadaProfile
Thomas WestDivision President of Diagnostics SolutionsProfile
Peter ValentiDivision President- Breast and Skeletal HealthProfile
Allison BeboSenior Vice President - Human ResourcesProfile
Michael WattsVice President IR Contact OfficerProfile
Robert McMahonCFOProfile
Karleen ObertonCFO, Chief Accounting OfficerProfile
Eric ComptonCOOProfile
Wayne WilsonIndependent DirectorProfile
Namal NawanaDirectorProfile
Sally CrawfordIndependent DirectorProfile
Ludwig HantsonDirectorProfile
Samuel MerksamerIndependent DirectorProfile
Christiana StamoulisDirector and Member of Corporate Devel. CommitteeProfile
Lawrence LevyIndependent DirectorProfile
Elaine UllianIndependent DirectorProfile
Amy WendellDirectorProfile
Scott GarrettIndependent DirectorProfile
Nancy LeamingIndependent DirectorProfile
Charles DockendorffDirectorProfile
Jonathan ChristodoroIndependent DirectorProfile
Al KildaniSenior Director - Investor RelationsProfile
Mark IrvingVP SecretaryProfile
Peter DunneSenior ResourcesProfile
Erik AndersonDivision SolutionsProfile
Essex MitchellChief OfficerProfile
Monica BerthelotVP StaffProfile
Paul MalenchiniChief OfficerProfile
Benjamin CohnPrincipal Chief Accounting OfficerProfile
Kevin ThornalGroup SolutionsProfile
Scott ChristensenQuality ChainProfile
Elisabeth HellmannSr CommunicationsProfile
John GriffinGeneral CounselProfile
Mike KellyChief AffairsProfile
Ryan SimonVice RelationsProfile
Brandon SchnittkerDivision SolutionsProfile

About Hologic Management Performance

The success or failure of an entity such as Hologic often depends on how effective the management is. Hologic management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Hologic management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Hologic management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.08  0.09 
Return On Capital Employed 0.1  0.08 
Return On Assets 0.06  0.03 
Return On Equity 0.08  0.09 
The data published in Hologic's official financial statements usually reflect Hologic's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Hologic. For example, before you start analyzing numbers published by Hologic accountants, it's critical to develop an understanding of what Hologic's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Hologic's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Hologic's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Hologic's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Hologic. Please utilize our Beneish M Score to check the likelihood of Hologic's management manipulating its earnings.

Hologic Workforce Analysis

Traditionally, organizations such as Hologic use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Hologic within its industry.

Hologic Manpower Efficiency

Return on Hologic Manpower

Revenue Per Employee576.6K
Revenue Per Executive98.3M
Net Income Per Employee65.2K
Net Income Per Executive11.1M
Working Capital Per Employee425.9K
Working Capital Per Executive72.6M
When determining whether Hologic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hologic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hologic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hologic Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hologic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Hologic Stock please use our How to Invest in Hologic guide.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Hologic Stock analysis

When running Hologic's price analysis, check to measure Hologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hologic is operating at the current time. Most of Hologic's value examination focuses on studying past and present price action to predict the probability of Hologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hologic's price. Additionally, you may evaluate how the addition of Hologic to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEOs Directory
Screen CEOs from public companies around the world
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Hologic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hologic. If investors know Hologic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hologic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.373
Earnings Share
2.11
Revenue Per Share
16.228
Quarterly Revenue Growth
(0.06)
Return On Assets
0.0649
The market value of Hologic is measured differently than its book value, which is the value of Hologic that is recorded on the company's balance sheet. Investors also form their own opinion of Hologic's value that differs from its market value or its book value, called intrinsic value, which is Hologic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hologic's market value can be influenced by many factors that don't directly affect Hologic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hologic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hologic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hologic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.